Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;79(10):1281-1290.
doi: 10.1007/s00228-023-03537-w. Epub 2023 Jul 18.

Impact of tofogliflozin on hepatic outcomes: a systematic review

Mani Pathak  1 , Rizwana Parveen  1 , Parvej Khan  1 , Nilanjan Saha  1 , Nidhi Agarwal  2
Affiliations

Impact of tofogliflozin on hepatic outcomes: a systematic review

Mani Pathak et al. Eur J Clin Pharmacol. 2023 Oct.

Abstract

Purpose: Studies have demonstrated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients. The aim was to review the effect of tofogliflozin on hepatic outcomes in T2DM patients.

Methods: A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised clinical trials of tofogliflozin by applying predetermined inclusion and exclusion criteria.

Results: A total number of four randomised clinical trials, including 226 subjects, were included in the review. There was a significant decrease in aspartate aminotransferase (AST) and alanine transaminase (ALT) levels in the tofogliflozin group as compared to the control or active comparator groups. Additionally, gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) levels were also significantly decreased in the tofogliflozin group. However, no significant difference was observed in levels of adiponectin.

Conclusion: Overall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM.

Keywords: ALT; AST; GGT; MRI-PDFF; Tofogliflozin; Tofogliflozin monohydrate; Type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. (2023) Diabetes. In: Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes - PMC - DOI
    1. Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomised, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2):298–305 - PubMed - DOI
    1. Mohamed J, Nafizah AN, Zariyantey AH, Budin S (2016) Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J 16(2)16:e132–141
    1. Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172(3):367–379 - PubMed - PMC - DOI
    1. Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7(4):313–324 - PubMed - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources